Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

Next Previous
X
Search
Trial Profile

Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary) ; Deferiprone (Primary)
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms START
  • Sponsors ApoPharma; Chiesi

    • Most Recent Events

    • 17 Jun 2022 Primary endpoint (The percentage of patients in each treatment group who still have a serum ferritin level 1000 micrograms per liter (g/L) at Month 12) has been met, as per results presented at the 27th Congress of the European Haematology Association.
    • 17 Jun 2022 Results assessing ability of early-start DFP to shuttle iron to transferrin in infants and young children with transfusion-dependent beta thalassemia using transferrin-saturation (TSAT) measurements, presented at the 27th Congress of the European Haematology Association.
    • 14 Dec 2021 Results assessing safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top